Potential anticancer properties and mechanisms of action of formononetin
Nature, a vast reservoir of pharmacologically active molecules, has been most promising
source of drug leads for the cure of various pathological conditions. Formononetin is one of …
source of drug leads for the cure of various pathological conditions. Formononetin is one of …
[HTML][HTML] Current molecular markers of melanoma and treatment targets
Melanoma is a deadly skin cancer that becomes especially difficult to treat after it
metastasizes. Timely identification of melanoma is critical for effective therapy, but …
metastasizes. Timely identification of melanoma is critical for effective therapy, but …
[HTML][HTML] Long non-coding RNA Rpph1 promotes inflammation and proliferation of mesangial cells in diabetic nephropathy via an interaction with Gal-3
P Zhang, Y Sun, R Peng, W Chen, X Fu, L Zhang… - Cell death & …, 2019 - nature.com
Diabetic nephropathy (DN) is one of the most significant complications of diabetes and is the
primary cause of end-stage kidney disease. Cumulating evidence has shown that renal …
primary cause of end-stage kidney disease. Cumulating evidence has shown that renal …
[HTML][HTML] Pan-cancer analysis identifies telomerase-associated signatures and cancer subtypes
Background Cancer cells become immortalized through telomere maintenance
mechanisms, such as telomerase reverse transcriptase (TERT) activation. In addition to …
mechanisms, such as telomerase reverse transcriptase (TERT) activation. In addition to …
Antitumor activity of luteolin in human colon cancer SW620 cells is mediated by the ERK/FOXO3a signaling pathway
The aim of this study was to investigate the mechanism of the anticancer activity of luteolin in
metastatic human colon cancer SW620 cells. Luteolin dose-dependently reduced the …
metastatic human colon cancer SW620 cells. Luteolin dose-dependently reduced the …
PADI2‐catalyzed MEK1 citrullination activates ERK1/2 and promotes IGF2BP1‐mediated SOX2 mRNA stability in endometrial cancer
T Xue, X Liu, M Zhang, QE, S Liu, M Zou, Y Li… - Advanced …, 2021 - Wiley Online Library
Peptidylarginine deiminase II (PADI2) converts positively charged arginine residues to
neutrally charged citrulline, and this activity has been associated with the onset and …
neutrally charged citrulline, and this activity has been associated with the onset and …
[HTML][HTML] Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies
The mitogen-activated protein kinase (MAPK) pathways are crucial regulators of the cellular
processes that fuel the malignant transformation of normal cells. The molecular aberrations …
processes that fuel the malignant transformation of normal cells. The molecular aberrations …
Potential mechanisms of action of dietary phytochemicals for cancer prevention by targeting cellular signaling transduction pathways
H Chen, RH Liu - Journal of agricultural and food chemistry, 2018 - ACS Publications
Cancer is a severe health problem that significantly undermines life span and quality.
Dietary approach helps provide preventive, nontoxic, and economical strategies against …
Dietary approach helps provide preventive, nontoxic, and economical strategies against …
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid …
MW Kieran, B Geoerger, IJ Dunkel, A Broniscer… - Clinical Cancer …, 2019 - AACR
Abstract Purpose: The 2-part, phase I/IIa, open-label study (NCT01677741) sought to
determine the safety, tolerability, pharmacokinetics, and preliminary activity of dabrafenib in …
determine the safety, tolerability, pharmacokinetics, and preliminary activity of dabrafenib in …
[HTML][HTML] Phase II study of selumetinib in children and young adults with tumors harboring activating mitogen-activated protein kinase pathway genetic alterations: arm …
OS Eckstein, CE Allen, PM Williams… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE The NCI-COG Pediatric MATCH trial assigns patients age 1-21 years with
relapsed or refractory solid tumors, lymphomas, and histiocytic disorders to phase II studies …
relapsed or refractory solid tumors, lymphomas, and histiocytic disorders to phase II studies …